JOURNAL BROWSE
Search
Advanced SearchSearch Tips
131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study
Ma, Jun; Wang, Jian-Hua;
  PDF(new window)
 Abstract
Objective: This study evaluated the safety and objective response of combining -labeled-metuximab (Licartin) with transarterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC). Materials and Methods: In a multicenter open-label clinical trial, 341 enrolled patients with stage III/IV HCC according to TNM criteria were nonrandomly assigned to a trial group (n
 Keywords
Hepatocellular carcinoma;iodine radioisotopes;antibody monoclonal;radioimmunotherapy;clinical study;
 Language
English
 Cited by
1.
Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients,;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 5, pp.2485-2490 crossref(new window)
2.
Transcatheter Arterial Chemoembolization Plus 131I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis,;;;;

Korean Journal of Radiology, 2016. vol.17. 6, pp.882-892 crossref(new window)
 References
1.
Aitken KL, Hawkins MA (2014). The role of radiotherapy and chemoradiation in the management of primary liver tumours. Clin Oncol (R Coll Radiol), 26, 569-80. crossref(new window)

2.
Alloni D, Cutaia C, Mariotti L, Friedland W, Ottolenghi A (2014). Modeling dose deposition and DNA damage due to low-energy $\beta$(-) emitters. Radiat Res, 182, 322-30. crossref(new window)

3.
Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011). Management of hepatocellular carcinoma: an update. AASLD practice guideline. Hepatol, 53, 1020-2. crossref(new window)

4.
Chen ZN, Mi L, Xu J, et al (2006). Targeting radioimmunotherapy of hepatocellular carcinoma with iodine ($^{131}I$) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys, 65, 435-44. crossref(new window)

5.
Chiesa C, Mira M, Maccauro M, et al (2012). A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging, 56, 503-8.

6.
European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer (2012). EASL-EORTC clinical practice guidelines: management of hepatocellulcer carcinoma. J Hepatol, 56, 908-43. crossref(new window)

7.
Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. crossref(new window)

8.
Goldenberg DM, Sharkey RM (2006). Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Imaging, 50, 248-64.

9.
Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. crossref(new window)

10.
Jiang W, Zeng ZC (2013). Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma? Oncol, 84, 69-74. crossref(new window)

11.
Juweid ME, Zhang CH, Blumenthal RD, et al (1997). Factors influencing hematologic toxicity of radioimmunotherapy with $^{131}I$-labeled anti-carcinoembryonic antigen antibodies. Cancer, 80, 2749-53. crossref(new window)

12.
Kassis AI, Adelstein SJ (2005). Radiobiologic principles in radionuclide therapy. J Nucl Med, 46, 4-12.

13.
Lambert B, Van de Wiele C (2005). Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Mol Imaging, 32, 980-9. crossref(new window)

14.
Lau WY, Lai EC, Leung TW, Yu SC (2008). Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trialupdate on 5-year and 10-year survival. Ann Surg, 247, 43-8. crossref(new window)

15.
Lencioni R, Crocetti L (2012). Local-regional treatment of hepatocellular carcinoma. Radiol, 262, 43-58. crossref(new window)

16.
Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellualr carcinoma. J Natl Cancer Inst, 100, 698-711. crossref(new window)

17.
Ministry of Health of the People's Republic of China (2011). Diagnosis, management and treatment of hepatocellular caricnoma (V2011). J Clin Heptol, 27, 1141-59.

18.
Pinter M, Hucke F, Graziadei I, et al (2012). Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiol, 263, 590-9. crossref(new window)

19.
Salem R, Mazzaferro V, Sangro B (2013). Yttrium 90 radioembolization for the treatment of hepatocellular caricinoma: biological lessons, current challenges, and clinical perspectives. Hepatol, 58, 2188-97. crossref(new window)

20.
Sgouros G (2005). Dosimetry of internal emitters. J Nucl Med, 46, 18-27.

21.
Wu L, Yang YF, Ge NJ, et al (2012). Hepatic artery injection of $^{131}I$-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur J Nucl Med Mol Imaging, 39, 1306-15. crossref(new window)

22.
Xu J, Shen ZY, Chen XG, et al (2007b). A randomized controlled trail of licartin for preventing hepatoma recurrence after liver transplantation. Hepatol, 45, 269-76. crossref(new window)

23.
Xu J, Xu HY, Zhang Q, et al (2007a). HAb18G/CD147 functions in invasion and metastasis of hepatocelluar carcinoma. Mol Cancer Res, 5, 605-14. crossref(new window)

24.
Zanzonico PB, Divgi C (2008). Patient-specific radiation dosmetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol. Semin Nucl Med, 38, 30-9. crossref(new window)

25.
Zeng ZC, Tang ZY, Liu KD, et al (1998). Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with combination of surgery and intrahepatic arterial infusion of $^{131}I$-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol, 124, 275-80. crossref(new window)

26.
Zhang Z, Bian H, Feng Q, et al (2006). Biodistribution and localization of iodine-131 labeled metuximab in patients with hepatocellular caricinoma. Cancer Biol Ther, 5, 318-22. crossref(new window)